- 4-Week # shares sold: 10,000
- 12-Week # shares sold: 16,892
- 24-Week # shares sold: 20,836
Earnings estimates for these five stocks improved a lot this year -- and the technical charts also say buy.
Here are Monday's top research calls, including downgrades for Bristol-Myers Squibb, JPMorgan and Weyerhaeuser, and an upgrade for Merck.
Jim Cramer says this merger of beverage can makers is a travesty that should have never been approved because it is going to cost consumers.